Evidence map›Paper›PMID 36723728›Full record

ArticleBasic research in cardiology2023

Toll-like receptor-3 contributes to the development of aortic valve stenosis.

Sven Thomas Niepmann, Nicola Willemsen, Ann Sophie Boucher, Marta Stei, Philip Goody, Andreas Zietzer, Marko Bulic, Hannah Billig, Alexandru Odainic, Christina Katharina Weisheit and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Basic research in cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Sven Thomas Niepmann *Heart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany. sven.niepmann@ukbonn.de.ORCID http://orcid.org/0000-0001-8095-5824
Nicola Willemsen *Heart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Ann Sophie BoucherHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Marta SteiHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Philip GoodyHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Andreas ZietzerHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Marko BulicHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Hannah BilligHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Alexandru OdainicInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
Christina Katharina WeisheitDepartment of Anaesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany.
Christine QuastCardiovascular Research Laboratory, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Matti AdamClinic for Cardiology, University Hospital Cologne, Cologne, Germany.
Susanne V SchmidtInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
Farhad BakhtiaryHeart Center Bonn, Clinic for Heard Surgery, University Hospital Bonn, Bonn, Germany.
Felix JansenHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Georg NickenigHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
Eike LatzInstitute of Innate Immunity, University Hospital Bonn, Bonn, Germany.
Sebastian ZimmerHeart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.
University Hospital Bonn · DEThe University of Melbourne · AUUniversity Hospital Cologne · DE

Funding

Deutsche Forschungsgemeinschaft 388169927Deutsche Forschungsgemeinschaft 397484323
6 · The paper itself

Abstract

Aortic valve stenosis (AS) development is driven by distinct molecular and cellular mechanisms which include inflammatory pathways. Toll-like-receptor-3 (TLR3) is a lysosomal pattern-recognition receptor that binds double-stranded RNA and promotes pro-inflammatory cellular responses. In recent years, TLR3 has emerged as a major regulator of vascular inflammation. The exact role of TLR3 in the development of AS has not been investigated. Isolated human valvular interstitial cells (VICs) were stimulated with the TLR3-agonist polyIC and the resulting pro-inflammatory and pro-osteogenic response measured. Severe AS was induced in wildtype- and TLR3

Indexed as

Aortic Valve StenosisCalcinosisAnimalsAortic ValveCells, CulturedEndothelial CellsHumansMiceToll-Like Receptor 3Toll-Like Receptor 3Aortic valve stenosisInnate immune systemToll-like receptorsValvular endothelial cellsValvular interstitial cells

Identifiers

PMID36723728
PMCPMC9892139
OpenAlexW4318755143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.